FDA approves Lerochol autoinjector and updates indication for monthly PCSK9 therapy

The new device provides adults with hypercholesterolaemia with an additional self-administration option for once-monthly Lerochol alongside the existing pre-filled syringe.

The US Food and Drug Administration (FDA) has approved a single-use autoinjector for Lerochol (lerodalcibep-liga) 300 mg/1.2 mL and updated the indication statement for the PCSK9 inhibitor, which is used alongside diet and exercise to reduce LDL-C in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia (HeFH).

The approval adds a new administration option for patients prescribed the once-monthly therapy, with US availability of the autoinjector expected by January 2027.

Field	Content
Alert Type	Drug Approval
Drug Name	Lerochol (lerodalcibep-liga)
Indication	As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia (HeFH).
Therapy Area(s)	Cardiovascular disease; Lipid management
Geography	United States (FDA)
What Happened	On 17 August 2026, the FDA approved a single-use autoinjector for Lerochol (lerodalcibep-liga) 300 mg/1.2 mL, providing an additional administration option alongside the existing pre-filled syringe. Lerochol is administered subcutaneously once monthly. The FDA also approved updated indication wording stating that cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk of major adverse cardiovascular events in adults at increased risk when treated with statins or monoclonal antibody PCSK9 inhibitors added to statin therapy. Lerochol itself was originally FDA approved in December 2025.
Why It Matters	Long-term lipid-lowering treatment can make administration method a practical consideration for patients and clinicians. The pressure-activated autoinjector provides another way for eligible patients to self-administer their monthly Lerochol dose while retaining the pre-filled syringe as an alternative; however, the effect of the new device on adherence or clinical outcomes has not been established.
Supporting Context	Lerochol is a third-generation PCSK9 inhibitor comprising an engineered PCSK9-binding adnectin fused to human serum albumin to extend its plasma half-life. The once-monthly treatment can be stored at room temperature for up to 90 days, providing additional flexibility around storage and administration.
Key Takeaway	FDA approval of the Lerochol autoinjector gives eligible patients an additional self-administration option for once-monthly PCSK9-directed LDL-C lowering.
What to Watch	LIB Therapeutics expects the autoinjector to become available in the US by January 2027. Commercial availability, insurance coverage and reimbursement are separate from FDA approval, with the company expecting coverage to expand during 2027.
Primary Source	https://www.businesswire.com/news/home/20260817106971/en/U.S.-Food-and-Drug-Administration-Approves-an-Autoinjector-Version-of-LEROCHOL-lerodalcibep-liga-and-Updated-Indication
Relevant Date	17 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com